Novavax COVID-19 vaccine (redirect from SARS-CoV-2 rS (NVX-CoV2373))
announced development of a vaccine candidate, codenamed NVX-CoV2373, to establish immunity to SARS-CoV-2. Novavax's work is in competition for vaccine development...
72 KB (5,499 words) - 04:38, 12 August 2024
company redirected its efforts to focus on development and approval of its NVX-CoV2373 vaccine for COVID-19. The COVID-19 vaccine Nuvaxovid was approved in...
31 KB (2,841 words) - 13:22, 18 June 2024
also reached an agreement with Novavax for the production of Novavax's NVX-CoV2373 (Covovax) vaccine for India and other low and middle-income countries...
19 KB (1,593 words) - 16:38, 7 August 2024
rolling review of NVX-CoV2373, a COVID‑19 vaccine being developed by Novavax CZ AS (a subsidiary of Novavax, Inc.) and a rolling review of CVnCoV, a COVID‑19...
122 KB (11,033 words) - 22:07, 17 July 2024
SARS-CoV-2 recombinant spike protein nanoparticle with adjuvant $1.6 billion for advance commercial-scale manufacturing July 7, 2020 NVX‑CoV2373 Funding...
71 KB (5,902 words) - 08:05, 17 June 2024
COVID-19 pandemic (redirect from 2019-20 outbreak of novel coronavirus (2019-nCoV))
First Approval of the Protein-Based Adjuvanted Nuvaxovid (NVX-CoV2373) Novavax Vaccine for SARS-CoV-2 Could Increase Vaccine Uptake and Provide Immune Protection...
368 KB (32,620 words) - 06:47, 9 August 2024
memorandum of understanding with Novavax to pursue manufacturing its NVX-CoV2373 vaccine at the Biologics Manufacturing Centre. In September 2020, President...
54 KB (5,526 words) - 04:04, 17 June 2024
Australia's first human trials of a candidate COVID-19 vaccine was Novavax's NVX-CoV2373 which began in Melbourne by 26 May 2020. In a February 2021 pre-budget...
275 KB (26,611 words) - 05:59, 10 August 2024
an emergency use listing (EUL) for NVX-CoV2373, expanding the basket of WHO-validated vaccines against the SARS-CoV-2 virus. World Health Organization...
14 KB (1,168 words) - 17:20, 16 June 2024
Australia's first human trials of a candidate COVID-19 vaccine, Novavax's NVX-CoV2373, began in Melbourne. On 6 June, both New South Wales and Victoria reported...
123 KB (11,747 words) - 13:02, 20 June 2024